NYSE:RCUS Arcus Biosciences (RCUS) Stock Price, News & Analysis $30.14 +0.62 (+2.10%) As of 08/21/2026 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arcus Biosciences Stock (NYSE:RCUS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arcus Biosciences alerts:Sign Up Key Stats Today's Range$29.74▼$30.5650-Day Range$23.60▼$31.1552-Week Range$10.07▼$31.74Volume1.06 million shsAverage Volume1.24 million shsMarket Capitalization$3.84 billionP/E RatioN/ADividend YieldN/APrice Target$37.80Consensus RatingModerate Buy Company Overview Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells. The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody. Additional pipeline assets explore dual checkpoint blockade and next-generation immune modulators. Arcus conducts multi-center clinical trials across North America, Europe and Asia, collaborating with academic institutions and global partners to advance its oncology portfolio. Founded in 2015 and headquartered in Redwood City, California, Arcus completed its initial public offering on the New York Stock Exchange in June 2020 under the ticker RCUS. The company has since forged strategic alliances with leading biopharmaceutical firms to accelerate clinical development and broaden the potential application of its immuno-oncology therapeutics. Arcus is led by President and Chief Executive Officer Terry Rosen, who co-founded the company and brings extensive experience in biotech leadership and oncology drug development. The senior management team combines expertise in translational medicine, clinical operations and commercial strategy to guide Arcus toward its goal of delivering new treatment options for patients with cancer.AI Generated. May Contain Errors. Read More Arcus Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreRCUS MarketRank™: Arcus Biosciences scored higher than 60% of companies evaluated by MarketBeat, and ranked 285th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingArcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on no strong buy ratings, 8 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialArcus Biosciences has a consensus price target of $37.80, representing about 25.4% upside from its current price of $30.14.Amount of Analyst CoverageArcus Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arcus Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arcus Biosciences are expected to grow in the coming year, from ($3.53) to ($3.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is -7.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is -7.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 8.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arcus Biosciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.15% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Arcus Biosciences has recently increased by 4.45%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.71 News SentimentArcus Biosciences has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Arcus Biosciences this week, compared to 5 articles on an average week.Search Interest3 people have searched for RCUS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows1 people have added Arcus Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,975,354.00 in company stock.Percentage Held by Insiders7.60% of the stock of Arcus Biosciences is held by insiders.Percentage Held by Institutions92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcus Biosciences' insider trading history. Receive RCUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RCUS Stock News HeadlinesArcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 22 at 2:14 AM | americanbankingnews.comKuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law FirmAugust 19, 2026 | prnewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.August 23 at 1:00 AM | Banyan Hill Publishing (Ad)Arcus Biosciences Bets Big on Casdatifan PipelineAugust 19, 2026 | theglobeandmail.comCould Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?August 13, 2026 | insidermonkey.comArcus Biosciences (RCUS) Q2 2026 Earnings Call TranscriptAugust 13, 2026 | finance.yahoo.comArcus Biosciences Announces New Employment Inducement GrantsAugust 11, 2026 | businesswire.comArcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley SaysAugust 11, 2026 | finance.yahoo.comSee More Headlines RCUS Stock Analysis - Frequently Asked Questions How have RCUS shares performed this year? Arcus Biosciences' stock was trading at $23.90 at the beginning of the year. Since then, RCUS shares have increased by 26.1% and is now trading at $30.14. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences, Inc. (NYSE:RCUS) posted its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.17. The business's revenue for the quarter was down 74.4% on a year-over-year basis. Read the conference call transcript. When did Arcus Biosciences IPO? Arcus Biosciences (RCUS) raised $112 million in an initial public offering on Thursday, March 15th 2018. The company issued 8,000,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO. Who are Arcus Biosciences' major shareholders? Arcus Biosciences' top institutional shareholders include BlackRock Inc. (13.05%), Wellington Management Group LLP (4.63%), Montanova Capital LLC (3.75%) and Parkman Healthcare Partners LLC (0.72%). Insiders that own company stock include Gilead Sciences, Inc, Terry J Rosen, Juan C Jaen, Jennifer Jarrett, Carolyn C Tang, Robert C Goeltz II, Richard Markus, Alexander Azoy and Yasunori Kaneko. View institutional ownership trends. How do I buy shares of Arcus Biosciences? Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcus Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings8/05/2026Today8/23/2026Next Earnings (Estimated)10/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 RCUS's financial health is in the Green zone, according to TradeSmith. RCUS has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:RCUS CIK1724521 Webwww.arcusbio.com Phone(510) 694-6200FaxN/AEmployees500Year Founded2015Price Target and Rating Average Price Target for Arcus Biosciences$37.80 High Price Target$47.00 Low Price Target$23.00 Potential Upside/Downside+25.4%Consensus RatingModerate Buy Rating Score (0-4)2.58 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($3.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$353 million Net Margins-393.16% Pretax Margin-393.16% Return on Equity-89.54% Return on Assets-45.61% Debt Debt-to-Equity Ratio0.22 Current Ratio3.82 Quick Ratio3.82 Sales & Book Value Annual Sales$247 million Price / Sales15.54 Cash FlowN/A Price / Cash FlowN/A Book Value$3.64 per share Price / Book8.28Miscellaneous Outstanding Shares127,330,000Free Float117,656,000Market Cap$3.84 billion OptionableOptionable Beta0.80 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NYSE:RCUS) was last updated on 8/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
